Journal
CLINICAL INFECTIOUS DISEASES
Volume 62, Issue 2, Pages 258-261Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/civ841
Keywords
immune reconstitution inflammatory syndrome; infliximab; mycobacterial infection
Categories
Funding
- NCI NIH HHS [HHSN261200800001E] Funding Source: Medline
- PHS HHS [261200800001E] Funding Source: Medline
- CCR NIH HHS [HHSN261200800001C] Funding Source: Medline
Ask authors/readers for more resources
The management of corticosteroid refractory immune reconstitution inflammatory syndrome (IRIS) is currently unclear. Infliximab administration was associated with clinical improvement without significant adverse events in 3 patients with mycobacterial IRIS. Immunologic and virologic responses to antiretroviral therapy were unaffected. Tumor necrosis factor blockade may be beneficial for IRIS and warrants further study in clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
